Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

A nonresponding small cell lung carcinoma.

Niels B Pronk1, Albert J Polman, Lotus Sterk

  • 1Medisch Spectrum Enschede, Enschede, The Netherlands. pronkniels@hotmail.com

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|March 4, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Clinical pharmacokinetics·2026
Same author

First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026
Same author

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

Future oncology (London, England)·2026
Same author

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.

The Lancet. Respiratory medicine·2026
Same journal

Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Is Less Actually More? Precision Is the Key!

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles

This case study details a patient with limited small cell lung cancer experiencing persistent disease and syndrome of inappropriate antidiuretic hormone. Surgical lobectomy was used to achieve local control after failed therapies.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pulmonology

Background:

  • Small cell lung carcinoma (SCLC) is an aggressive cancer.
  • Syndrome of inappropriate antidiuretic hormone (SIADH) is a common paraneoplastic syndrome in SCLC.
  • Limited disease SCLC typically requires multimodal therapy.

Observation:

  • A patient with limited disease SCLC presented with persistent disease after chemoradiotherapy and second-line chemotherapy.
  • The patient also suffered from a persistent and problematic SIADH.
  • Local control remained a challenge despite systemic and radiation treatments.

Findings:

  • Surgical lobectomy was performed to achieve local control of the limited disease SCLC.
  • This case highlights the challenges in managing persistent SCLC and associated SIADH.

More Related Videos

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

  • Aggressive local treatment may be considered when systemic therapies fail.

    • Implications:

    • Lobectomy can be a viable option for achieving local control in select SCLC cases.
    • Multidisciplinary management is crucial for patients with refractory SCLC and SIADH.
    • Further research into optimal treatment strategies for persistent SCLC is warranted.